Proceedings from a CME symposium held at the 2018 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Ghassan Abou-Alfa, Josep M Llovet, Bert H O'Neil and Andrew X Zhu. (Video Program)
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of hepatocellular carcinoma (HCC).
OVERVIEW OF ACTIVITY
HCC, the most common form of liver cancer, is a major cause of mortality globally, resulting in an estimated 600,000 deaths per year. The incidence rate of liver cancer in the United States has increased sharply, and it is estimated that approximately 42,220 new cases will be diagnosed in 2018 in this country and 30,200 individuals will die of the disease. Initial management is generally multidisciplinary in nature, and several potentially curative treatment modalities are available for patients with early-stage HCC. Unfortunately, for a number of reasons (eg, tumor extent, underlying liver dysfunction) many patients may not be amenable to potentially curative efforts, and median survival from time of diagnosis remains less than 1 year. This dismal prognosis has created the dramatic need for other therapeutic interventions and has spurred a rigorous research platform spanning several decades and most recently resulting in a number of new FDA approvals and various Phase III clinical trials.
Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making HCC management decisions in this dynamic clinical and research environment. However, in situations where multiple acceptable therapeutic options exist, such guidelines may not be particularly helpful at the time of decision-making. By exploring the perspectives of leading investigators regarding a number of clinical scenarios and reviewing key data sets, this activity will assist medical oncologists and other healthcare professionals in the development of evidence-based strategies for the treatment of HCC.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Ghassan Abou-Alfa, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York
Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Aptus Clinical, ASLAN Pharmaceuticals, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen Therapeutics, CASI Pharmaceuticals, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Debiopharm Group, Delcath Systems Inc, Eisai Inc, Gilead Sciences Inc, Halozyme Inc, Inovio Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Lilly, MedImmune Inc, Merck, Onxeo, PCI Biotech, Roche Laboratories Inc, Sanofi Genzyme, Servier, Silenseed Ltd, SillaJen, Sirtex Medical Ltd, Yakult Pharmaceutical Industry CO LTD; Contracted Research: Agios Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CASI Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Incyte Corporation, Lilly, MabVax Therapeutics Holdings Inc, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.
Josep M Llovet, MD, PhD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases, Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Professor of Research - ICREA
Director, Master in Translational Medicine
BCLC Group, Liver Unit, CIBERehd, IDIBAPS
Hospital ClĂnic de Barcelona
University of Barcelona
Barcelona, Spain
Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Lilly; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Celsion Corporation, Eisai Inc, Incyte Corporation, Lilly; Contracted Research: Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Eisai Inc, Incyte Corporation.
Bert H O'Neil, MD
Professor of Medicine
Director, Phase I and GI Malignancies Programs
Indiana University Simon Cancer Center
Indianapolis, Indiana
Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Halozyme Inc.
Andrew X Zhu, MD, PhD
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Lilly, Merck, Novartis, Sanofi Genzyme; Contracted Research: Bayer HealthCare Pharmaceuticals, Lilly, Merck, Novartis.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals and Exelixis Inc.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: March 2018
Expiration date: March 2019
(WIFI is recommended for best performance):